About Us

Related Links


Our major findings bring benefit to society, both in the UK and throughout the world. Explore our impact in the following case studies.

Preventing bone loss in patients treated for breast cancer

Our research into the link between breast cancer and bone loss led to changes in international guidelines and treatment

Almost 30,000 postmenopausal women in the UK develop breast cancer each year. Aromatase inhibitors (AIs) are a class of drug that significantly improve their survival rate.

Research undertaken by the University of Manchester confirmed, however... Read More

Improving outcomes of women diagnosed with and at increased risk of breast cancer

Over 1.5 million women who develop breast cancer each year have benefited from our research into treatment and prevention

Breast cancer is the most common cause of cancer and cancer mortality in women worldwide.

Research conducted at The University of Manchester on the treatment and prevention of breast cancer has benefited over 1.5 million women... Read More

The Development and Translation of Tamoxifen to the Clinic in Manchester

The first clinical trial of the drug was begun at the Christie Hospital, Manchester in December 1969

The Development and Translation of Tamoxifen to the Clinic in Manchester... Further Reading


Date:  20 June 201716:00
Speaker:  Nicholas Turner
From:  Institute of Cancer Research
Title:  TBC
Host:  Rob Clarke
Date:  04 July 201716:00
Speaker:  Richard Iggo
From:  Bergonié Cancer Institute - University of Bordeaux
Title:  The mammary ducts create a favourable microenvironment for xenografting of luminal and molecular apocrine breast tumours
Host:  Charles Streuli
Date:  14 September 201716:00
Speaker:  Mohamed Bentires-Alj
From:  University of Basel
Title:  TBA
Host:  Rob Clarke
Date:  05 October 201716:00
Speaker:  Daniel Rea - Breast Cancer Now Seminar
From:  Institute of Cancer and Genomic Sciences - University of Birmingham
Title:  TBA
Host:  Andrew Wardley